BOOK

Autor: Li, Mary Kathryn

Publikováno v: In Journal of Nutrition Education and Behavior February 2022 54(2):197-197

Resident-Led Research Policy and Power (RRPP): A Framework for Centering Community Voice in Participatory Research.

Autor: Hill Z; New York Academy of Medicine, New York, NY, USA. zhill@nyam.org., Taylor S; New York Academy of Medicine, New York, NY, USA., Kolack D; New York Academy of Medicine, New York, NY, USA., Maldonado G; New York Academy of Medicine, New York, NY, USA., Davis B; New York Academy of Medicine, New York, NY, USA., Medina B; New York Academy of Medicine, New York, NY, USA., Arias M; East Harlem Action Collaborative, New York, NY, USA., Arroyo C; East Harlem Action Collaborative, New York, NY, USA., Cotton S; East Harlem Action Collaborative, New York, NY, USA., de la Cruz M; East Harlem Action Collaborative, New York, NY, USA., Donadelle A; Union Settlement, New York, NY, USA., Martinez M; East Harlem Action Collaborative, New York, NY, USA., Starks-Payne C; East Harlem Action Collaborative, New York, NY, USA., Perez M; East Harlem Action Collaborative, New York, NY, USA., Sanchez C; East Harlem Action Collaborative, New York, NY, USA., Jimenez R; LSA Family Health Service, New York, NY, USA., Abdul-Mateen Z; |un|earth + bloom, New York, NY, USA., Bogard K; National Academy of Medicine, Washington, DC, USA.

Publikováno v: Journal of urban health : bulletin of the New York Academy of Medicine [J Urban Health] 2022 Aug; Vol. 99 (4), pp. 688-691. Date of Electronic Publication: 2022 Jun 29.

Leveraging science to inform social policy: How Ed Zigler created a movement.

Autor: Bogard K; New York Academy of Medicine, New York, NY, USA., Takanishi R; New America, Washington, DC, USA.

Publikováno v: Development and psychopathology [Dev Psychopathol] 2021 May; Vol. 33 (2), pp. 431-440.

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.

Autor: Manda S; Arizona Oncology/US Oncology Research, Tucson, AZ., Yimer HA; Texas Oncology/US Oncology Research, Tyler, TX., Noga SJ; Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan., Girnius S; Trihealth Cancer Institute, Cincinnati, OH., Yasenchak CA; Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR., Charu V; Pacific Cancer Medical Center, Anaheim, CA., Lyons R; Texas Oncology/US Oncology Research, San Antonio, TX., Aiello J; Patient Empowerment Network, San Jose, CA., Bogard K; Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan., Ferrari RH; Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan., Cherepanov D; Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan., Demers B; Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan., Lu V; Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan., Whidden P; Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan., Kambhampati S; Kansas City Veterans Affairs Medical Center, Kansas City, MO., Birhiray RE; Hematology Oncology of Indiana/American Oncology Network, Indianapolis, IN., Jhangiani HS; Compassionate Cancer Care Medical Group, Fountain Valley, CA., Boccia R; Center for Cancer and Blood Disorders, Bethesda, MD., Rifkin RM; Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO. Electronic address: robert.rifkin@usoncology.com.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2020 Nov; Vol. 20 (11), pp. e910-e925. Date of Electronic Publication: 2020 Jul 06.

P947: COMPARATIVE EFFECTIVENESS OF ORAL IXAZOMIB‐LENALIDOMIDE‐DEXAMETHASONE (IRD) AFTER INITIAL BORTEZOMIB (V)‐BASED INDUCTION VS PARENTERAL V‐BASED THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

Autor: Rifkin, R. M., Costello, C. L., Birhiray, R. E., Kambhampati, S., Richter, J., Abonour, R., Lee, H. C., Kim, Y. J., Ren, K., Stull, D. M., Cherepanov, D., Bogard, K., Noga, S. J., Girnius, S.

Publikováno v: HemaSphere; 2022 Supplement 3, Vol. 6, p837-838, 2p